<DOC>
	<DOC>NCT00174434</DOC>
	<brief_summary>This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Breast cancer with evidence of unresectable, locally recurrent or metastatic disease. Candidate for treatment with paclitaxel. Prior chemotherapy in the advanced disease setting. HER2 positive disease unless previously treated with trastuzumab.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>